Clinical Trial Update: Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

Phase II study results for MEDI4736 monotherapy in recurrent/metastatic PD-L1-positive squamous cell carcinoma of the head and neck have been posted after compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• MEDI4736 (Durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2018-06-18